Aliases & Classifications for Ocular Hyperemia

MalaCards integrated aliases for Ocular Hyperemia:

Name: Ocular Hyperemia 12 15 73
Hyperemia of Conjunctiva 12
Hyperemia Eye 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1248
SNOMED-CT 68 359610006 76849009
UMLS 73 C0155169

Summaries for Ocular Hyperemia

MalaCards based summary : Ocular Hyperemia, also known as hyperemia of conjunctiva, is related to adenoid hypertrophy and acid-labile subunit deficiency, and has symptoms including redness of eye An important gene associated with Ocular Hyperemia is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Pathways in cancer and Development IGF-1 receptor signaling. The drugs Bimatoprost and Timolol have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are homeostasis/metabolism and behavior/neurological

Related Diseases for Ocular Hyperemia

Diseases related to Ocular Hyperemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 12)
# Related Disease Score Top Affiliating Genes
1 adenoid hypertrophy 10.6 SOD1 TRPV1
2 acid-labile subunit deficiency 10.2 IGF2 IGFBP3
3 red-green color blindness 10.2 IGF2 RPE65
4 complete androgen insensitivity syndrome 10.2 IGF2 IGFBP3
5 hereditary wilms' tumor 10.1 ALK IGF2
6 retinal vasculitis 10.1 IFNB1 SOD1
7 fetal macrosomia 10.1 IGF2 IGFBP3
8 central nervous system disease 9.9 IFNB1 SOD1 TRPV1
9 nervous system disease 9.8 IFNB1 SOD1 TRPV1
10 laron syndrome 9.6 IGF2 IGFBP3
11 prader-willi syndrome 9.6 EHMT2 IGF2 IGFBP3
12 ewing sarcoma 8.8 ALK IFNB1 IGF2 IGFBP3

Graphical network of the top 20 diseases related to Ocular Hyperemia:



Diseases related to Ocular Hyperemia

Symptoms & Phenotypes for Ocular Hyperemia

UMLS symptoms related to Ocular Hyperemia:


redness of eye

MGI Mouse Phenotypes related to Ocular Hyperemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.14 PTGER3 ALK IFNB1 IGF2 BCL2L11 IGFBP3
2 behavior/neurological MP:0005386 10.13 PTGER3 EHMT2 ALK IGF2 IGFBP3 RPE65
3 immune system MP:0005387 10.11 EHMT2 IFNB1 IGF2 BCL2L11 CD40 PRTN3
4 hematopoietic system MP:0005397 10.09 EFS EHMT2 IFNB1 IGF2 BCL2L11 CD40
5 endocrine/exocrine gland MP:0005379 10 EHMT2 ALK BCL2L11 IGF2 IGFBP3 CD40
6 integument MP:0010771 9.92 PTGER3 ALK IGF2 BCL2L11 IGFBP3 SLC6A2
7 nervous system MP:0003631 9.85 EHMT2 ALK IFNB1 IGF2 BCL2L11 CD40
8 neoplasm MP:0002006 9.65 IFNB1 ALK BCL2L11 TRPV1 SOD1
9 pigmentation MP:0001186 9.26 ALK BCL2L11 IGFBP3 RPE65
10 renal/urinary system MP:0005367 9.17 PTGER3 IGF2 BCL2L11 IGFBP3 CD40 EFS

Drugs & Therapeutics for Ocular Hyperemia

Drugs for Ocular Hyperemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bimatoprost Approved, Investigational Phase 4 155206-00-1 5311027
2
Timolol Approved Phase 4 26839-75-8 33624 5478
3
Travoprost Approved Phase 4,Phase 3 157283-68-6 5282226
4
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
5
Maleic acid Experimental Phase 4 110-16-7 444266
6 Antihypertensive Agents Phase 4,Phase 3,Phase 2
7 Ophthalmic Solutions Phase 4,Phase 2,Phase 3
8 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3
9 Adrenergic Agents Phase 4,Phase 3,Phase 2
10 Adrenergic Antagonists Phase 4,Phase 2
11 Adrenergic beta-Antagonists Phase 4
12 Anti-Arrhythmia Agents Phase 4
13 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
14 Anti-Infective Agents Phase 4
15 Anti-Infective Agents, Local Phase 4
16 Benzalkonium Compounds Phase 4
17
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
18
Ephedrine Approved Phase 3 299-42-3 9294
19
Fexofenadine Approved, Investigational Phase 3 83799-24-0 3348
20
Loratadine Approved, Investigational Phase 3 79794-75-5 3957
21
Pseudoephedrine Approved Phase 3 90-82-4 7028
22
Adalimumab Approved Phase 2, Phase 3 331731-18-1 16219006
23 Analgesics Phase 3
24 Analgesics, Non-Narcotic Phase 3
25 Anti-Allergic Agents Phase 3
26 Anti-Inflammatory Agents Phase 3,Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 3
28 Antirheumatic Agents Phase 3,Phase 2
29 Histamine Antagonists Phase 3
30 Histamine H1 Antagonists Phase 3
31 Histamine H1 Antagonists, Non-Sedating Phase 3
32
Histamine Phosphate Phase 3 51-74-1 65513
33 Olopatadine Hydrochloride Phase 3
34 Peripheral Nervous System Agents Phase 3
35 Anti-Asthmatic Agents Phase 3
36 Antipruritics Phase 3
37 Autonomic Agents Phase 3
38 Bronchodilator Agents Phase 3
39 Central Nervous System Stimulants Phase 3
40 Dermatologic Agents Phase 3
41 Nasal Decongestants Phase 3
42 Respiratory System Agents Phase 3
43 Vasoconstrictor Agents Phase 3
44 Antibodies Phase 2, Phase 3
45 Antibodies, Monoclonal Phase 2, Phase 3
46 Immunoglobulins Phase 2, Phase 3
47
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
48
Phentolamine Approved Phase 2 50-60-2 5775
49 BB 1101 Phase 2
50 Dexamethasone acetate Phase 2 1177-87-3

Interventional clinical trials:

(show all 25)
# Name Status NCT ID Phase Drugs
1 A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH) Completed NCT01594970 Phase 4 Bimatoprost 0.01%
2 A Study of LUMIGAN® RC in the Clinical Setting Completed NCT01833741 Phase 4 Bimatoprost 0.01%
3 Efficacy of Changing to DUOTRAV® From Prior Therapy Completed NCT01327599 Phase 4 Travoprost 0.004%+Timolol 0.5% ophthalmic solution
4 An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN® Completed NCT01664039 Phase 4 Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
5 A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma Recruiting NCT02792803 Phase 4 Xalatan;Apo-Latanoprost;Co-Latanoprost
6 Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy Terminated NCT01514721 Phase 4 Travoprost/Timolol Maleate BAK-Free Fixed Combination
7 Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration Unknown status NCT02127463 Phase 2, Phase 3 MC-1101;MC-1101 Vehicle
8 AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis Completed NCT02161146 Phase 3 AGN-229666;Vehicle to AGN-229666;Olopatadine
9 Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis. Completed NCT01228630 Phase 3 Cloratadd-D;Allegra-D
10 An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis Completed NCT01037179 Phase 3 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
11 Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis Completed NCT01385826 Phase 2, Phase 3 Anti-tumor necrosis factor alpha monoclonal antibody;placebo
12 A Phase 3 Study of Reproxalap in Subjects With Allergic Conjunctivitis Recruiting NCT03494504 Phase 3 Reproxalap Ophthalmic Solution (0.25%);Reproxalap Ophthalmic Solution (0.5%);Vehicle Ophthalmic Solution
13 OTX-16-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-TP in Subjects With Open-Angle Glaucoma and Ocular Hypertension Recruiting NCT02914509 Phase 3 Travoprost
14 Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration Terminated NCT01601483 Phase 2, Phase 3 MC-1101;MC-1101 Vehicle
15 A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma Unknown status NCT02152774 Phase 2 Rho-Kinase Inhibitor
16 A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention Unknown status NCT02174991 Phase 2 Rho-Kinase Inhibitor (AR-12286)
17 A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt Unknown status NCT02173223 Phase 2 Rho-Kinase Inhibitor
18 Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis Completed NCT02062905 Phase 2 OTX-DP treatment
19 A Study of ADX-102 in Subjects With Allergic Conjunctivitis Completed NCT03012165 Phase 2 ADX-102 Ophthalmic Drops (0.5%);ADX-102 Ophthalmic Drops (0.1%);Vehicle of ADX-102 Ophthalmic Drops
20 The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Complaints Completed NCT01703559 Phase 2 Phentolamine mesylate ophthalmic solution
21 Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis Recruiting NCT03368339 Phase 2 PR013 (0.045%);PR013 (0.06%);Placebo
22 Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer Terminated NCT01137071 Phase 2
23 A Study of Bimatoprost 0.01% in the Clinical Setting Completed NCT01814761 Bimatoprost 0.01%
24 Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy. Completed NCT00801437 Xalacom
25 EyeBag Effectiveness in Meibomian Gland Dysfunction Completed NCT01870180 Not Applicable

Search NIH Clinical Center for Ocular Hyperemia

Genetic Tests for Ocular Hyperemia

Anatomical Context for Ocular Hyperemia

MalaCards organs/tissues related to Ocular Hyperemia:

41
Eye

Publications for Ocular Hyperemia

Articles related to Ocular Hyperemia:

# Title Authors Year
1
Seeing red: guiding the management of ocular hyperemia. ( 18528197 )
2008
2
External ocular hyperemia: a quantifiable indicator of spacecraft air quality. ( 8725467 )
1996
3
Automatic quantitative measurement of ocular hyperemia. ( 8974839 )
1995
4
Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. ( 7532135 )
1994
5
Degeneration release of norepinephrine causes transient ocular hyperemia mediated by prostaglandins. ( 4692259 )
1973

Variations for Ocular Hyperemia

Expression for Ocular Hyperemia

Search GEO for disease gene expression data for Ocular Hyperemia.

Pathways for Ocular Hyperemia

Pathways related to Ocular Hyperemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.18 ALK BCL2L11 IGF2 PTGER3
2
Show member pathways
10.9 BCL2L11 IGF2 IGFBP3
3 10.28 IGF2 IGFBP3

GO Terms for Ocular Hyperemia

Cellular components related to Ocular Hyperemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.32 ALK CD40 EFS IGF2 PRTN3 PTGER3

Biological processes related to Ocular Hyperemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.71 BCL2L11 IGFBP3 SOD1 TRPV1
2 regulation of apoptotic process GO:0042981 9.67 ALK BCL2L11 CD40 IGFBP3
3 activation of MAPK activity GO:0000187 9.61 ALK IGF2 SOD1
4 B cell proliferation GO:0042100 9.48 CD40 IFNB1
5 response to pain GO:0048265 9.46 SLC6A2 TRPV1
6 cellular response to ATP GO:0071318 9.32 SOD1 TRPV1
7 myeloid cell homeostasis GO:0002262 9.26 BCL2L11 SOD1
8 positive regulation of MAPK cascade GO:0043410 9.26 ALK CD40 IGF2 IGFBP3
9 regulation of organ growth GO:0046620 9.16 BCL2L11 SOD1
10 response to nutrient levels GO:0031667 8.92 CD40 EHMT2 IGF2 SOD1

Sources for Ocular Hyperemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....